Teva Pharmaceutical Industries Limited (NYSE: TEVA) Stock Competitors & Peer Comparison

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, TAK has a market cap of 65.3B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while TAK trades at $20.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas TAK's P/E ratio is 14.99. In terms of profitability, TEVA's ROE is +0.06%, compared to TAK's ROE of +0.05%. Regarding short-term risk, TEVA is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check TAK's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, HLN has a market cap of 40.3B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while HLN trades at $9.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas HLN's P/E ratio is 18.59. In terms of profitability, TEVA's ROE is +0.06%, compared to HLN's ROE of +0.10%. Regarding short-term risk, TEVA is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check HLN's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ZTS has a market cap of 33.5B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ZTS trades at $82.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ZTS's P/E ratio is 12.55. In terms of profitability, TEVA's ROE is +0.06%, compared to ZTS's ROE of +0.76%. Regarding short-term risk, TEVA is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZTS's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, VTRS has a market cap of 24.1B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while VTRS trades at $21.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas VTRS's P/E ratio is 8.36. In terms of profitability, TEVA's ROE is +0.06%, compared to VTRS's ROE of -0.04%. Regarding short-term risk, TEVA is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check VTRS's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TEVA's ROE is +0.06%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TEVA is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ITCI's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ELAN has a market cap of 13.2B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ELAN trades at $26.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ELAN's P/E ratio is 24.98. In terms of profitability, TEVA's ROE is +0.06%, compared to ELAN's ROE of -0.02%. Regarding short-term risk, TEVA is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ELAN's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, RDY has a market cap of 12.4B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while RDY trades at $14.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas RDY's P/E ratio is 31.57. In terms of profitability, TEVA's ROE is +0.06%, compared to RDY's ROE of +0.07%. Regarding short-term risk, TEVA is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check RDY's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TEVA's ROE is +0.06%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TEVA is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check CTLT's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ALKS trades at $47.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ALKS's P/E ratio is 50.41. In terms of profitability, TEVA's ROE is +0.06%, compared to ALKS's ROE of -0.00%. Regarding short-term risk, TEVA is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ALKS's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, AMRX has a market cap of 7.6B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while AMRX trades at $21.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas AMRX's P/E ratio is 24.12. In terms of profitability, TEVA's ROE is +0.06%, compared to AMRX's ROE of +1.32%. Regarding short-term risk, TEVA is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AMRX's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while LNTH trades at $101.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas LNTH's P/E ratio is 17.08. In terms of profitability, TEVA's ROE is +0.06%, compared to LNTH's ROE of +0.22%. Regarding short-term risk, TEVA is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check LNTH's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while INDV trades at $36.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas INDV's P/E ratio is 9.94. In terms of profitability, TEVA's ROE is +0.06%, compared to INDV's ROE of -3.53%. Regarding short-term risk, TEVA is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check INDV's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, BHC has a market cap of 3.1B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while BHC trades at $8.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas BHC's P/E ratio is 2.13. In terms of profitability, TEVA's ROE is +0.06%, compared to BHC's ROE of +0.59%. Regarding short-term risk, TEVA is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check BHC's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while RGC trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas RGC's P/E ratio is -541.00. In terms of profitability, TEVA's ROE is +0.06%, compared to RGC's ROE of -1.61%. Regarding short-term risk, TEVA is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check RGC's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, HCM has a market cap of 2.6B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while HCM trades at $15.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas HCM's P/E ratio is 145.84. In terms of profitability, TEVA's ROE is +0.06%, compared to HCM's ROE of +0.01%. Regarding short-term risk, TEVA is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check HCM's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, PRGO has a market cap of 2.3B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while PRGO trades at $16.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas PRGO's P/E ratio is 6.62. In terms of profitability, TEVA's ROE is +0.06%, compared to PRGO's ROE of -0.68%. Regarding short-term risk, TEVA is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check PRGO's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TEVA's ROE is +0.06%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TEVA is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check DCPH's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TEVA's ROE is +0.06%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, TEVA is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check AVDL's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ETON has a market cap of 2B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ETON trades at $68.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ETON's P/E ratio is 180.00. In terms of profitability, TEVA's ROE is +0.06%, compared to ETON's ROE of +1.05%. Regarding short-term risk, TEVA is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ETON's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, TRLV has a market cap of 1.9B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while TRLV trades at $11.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas TRLV's P/E ratio is -4.57. In terms of profitability, TEVA's ROE is +0.06%, compared to TRLV's ROE of -0.46%. Regarding short-term risk, TEVA is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TRLV's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TEVA's ROE is +0.06%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, TEVA is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check EMBCV's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TEVA's ROE is +0.06%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, TEVA is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check DVAX's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ALVO trades at $4.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ALVO's P/E ratio is -8.34. In terms of profitability, TEVA's ROE is +0.06%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, TEVA is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ALVO's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, SUPN has a market cap of 1.7B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while SUPN trades at $29.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas SUPN's P/E ratio is -38.89. In terms of profitability, TEVA's ROE is +0.06%, compared to SUPN's ROE of -3.53%. Regarding short-term risk, TEVA is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SUPN's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ALVOW has a market cap of 1.7B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ALVOW trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ALVOW's P/E ratio is 26.59. In terms of profitability, TEVA's ROE is +0.06%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, TEVA is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ALVOW's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ANIP trades at $71.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ANIP's P/E ratio is 8.65. In terms of profitability, TEVA's ROE is +0.06%, compared to ANIP's ROE of +0.20%. Regarding short-term risk, TEVA is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ANIP's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas TARO's P/E ratio is 30.05. In terms of profitability, TEVA's ROE is +0.06%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TEVA is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check TARO's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while PCRX trades at $36.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas PCRX's P/E ratio is 14.02. In terms of profitability, TEVA's ROE is +0.06%, compared to PCRX's ROE of +0.06%. Regarding short-term risk, TEVA is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check PCRX's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while PAHC trades at $35.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas PAHC's P/E ratio is 12.00. In terms of profitability, TEVA's ROE is +0.06%, compared to PAHC's ROE of +0.27%. Regarding short-term risk, TEVA is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check PAHC's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while CRON trades at $3.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas CRON's P/E ratio is 17.67. In terms of profitability, TEVA's ROE is +0.06%, compared to CRON's ROE of +0.05%. Regarding short-term risk, TEVA is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CRON's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while AMPH trades at $28.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas AMPH's P/E ratio is 9.76. In terms of profitability, TEVA's ROE is +0.06%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, TEVA is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AMPH's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while HROW trades at $29.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas HROW's P/E ratio is -29.67. In terms of profitability, TEVA's ROE is +0.06%, compared to HROW's ROE of -0.91%. Regarding short-term risk, TEVA is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check HROW's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TEVA's ROE is +0.06%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TEVA is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check PETQ's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, IRWD has a market cap of 806.2M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while IRWD trades at $4.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas IRWD's P/E ratio is 6.24. In terms of profitability, TEVA's ROE is +0.06%, compared to IRWD's ROE of -0.93%. Regarding short-term risk, TEVA is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check IRWD's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, COLL has a market cap of 771M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while COLL trades at $24.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas COLL's P/E ratio is 3.11. In terms of profitability, TEVA's ROE is +0.06%, compared to COLL's ROE of +0.12%. Regarding short-term risk, TEVA is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check COLL's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, EVO has a market cap of 600.3M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while EVO trades at $1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas EVO's P/E ratio is -2.39. In terms of profitability, TEVA's ROE is +0.06%, compared to EVO's ROE of -0.26%. Regarding short-term risk, TEVA is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check EVO's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TEVA's ROE is +0.06%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TEVA is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check BDSI's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, TKNO has a market cap of 541M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while TKNO trades at $8.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas TKNO's P/E ratio is -27.81. In terms of profitability, TEVA's ROE is +0.06%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, TEVA is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TKNO's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, EOLS has a market cap of 491.1M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while EOLS trades at $7.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas EOLS's P/E ratio is -23.50. In terms of profitability, TEVA's ROE is +0.06%, compared to EOLS's ROE of +1.03%. Regarding short-term risk, TEVA is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check EOLS's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, KMDA has a market cap of 469.1M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while KMDA trades at $8.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas KMDA's P/E ratio is 21.39. In terms of profitability, TEVA's ROE is +0.06%, compared to KMDA's ROE of +0.09%. Regarding short-term risk, TEVA is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check KMDA's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, AQST has a market cap of 450M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while AQST trades at $3.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas AQST's P/E ratio is -5.51. In terms of profitability, TEVA's ROE is +0.06%, compared to AQST's ROE of +2.55%. Regarding short-term risk, TEVA is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AQST's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ACB has a market cap of 332M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ACB trades at $5.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ACB's P/E ratio is -3.65. In terms of profitability, TEVA's ROE is +0.06%, compared to ACB's ROE of -0.15%. Regarding short-term risk, TEVA is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ACB's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, EBS has a market cap of 310.5M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while EBS trades at $6.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas EBS's P/E ratio is 4.19. In terms of profitability, TEVA's ROE is +0.06%, compared to EBS's ROE of -0.61%. Regarding short-term risk, TEVA is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check EBS's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TEVA's ROE is +0.06%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TEVA is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ALIM's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, TLRY has a market cap of 291.9M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while TLRY trades at $2.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas TLRY's P/E ratio is -1.86. In terms of profitability, TEVA's ROE is +0.06%, compared to TLRY's ROE of -0.10%. Regarding short-term risk, TEVA is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TLRY's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TEVA's ROE is +0.06%, compared to LNDC's ROE of +5.75%. Regarding short-term risk, TEVA is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check LNDC's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, CGC has a market cap of 256.1M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while CGC trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas CGC's P/E ratio is -1.35. In terms of profitability, TEVA's ROE is +0.06%, compared to CGC's ROE of -0.39%. Regarding short-term risk, TEVA is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CGC's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, LFCR has a market cap of 242.6M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while LFCR trades at $6.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas LFCR's P/E ratio is -5.04. In terms of profitability, TEVA's ROE is +0.06%, compared to LFCR's ROE of +3.82%. Regarding short-term risk, TEVA is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check LFCR's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TEVA's ROE is +0.06%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, TEVA is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TYHT's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, SIGA has a market cap of 225.6M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while SIGA trades at $3.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas SIGA's P/E ratio is 11.63. In terms of profitability, TEVA's ROE is +0.06%, compared to SIGA's ROE of +0.00%. Regarding short-term risk, TEVA is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SIGA's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas REPH's P/E ratio is -8.04. In terms of profitability, TEVA's ROE is +0.06%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TEVA is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check REPH's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, GLAS has a market cap of 166.8M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while GLAS trades at $1.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas GLAS's P/E ratio is -3.39. In terms of profitability, TEVA's ROE is +0.06%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, TEVA is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check GLAS's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas THTX's P/E ratio is -28.83. In terms of profitability, TEVA's ROE is +0.06%, compared to THTX's ROE of +0.36%. Regarding short-term risk, TEVA is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check THTX's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ASRT's P/E ratio is -7.10. In terms of profitability, TEVA's ROE is +0.06%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TEVA is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ASRT's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ORGO has a market cap of 136.3M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ORGO trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ORGO's P/E ratio is 35.00. In terms of profitability, TEVA's ROE is +0.06%, compared to ORGO's ROE of -0.46%. Regarding short-term risk, TEVA is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ORGO's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, DERM has a market cap of 125.3M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while DERM trades at $4.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas DERM's P/E ratio is -20.18. In terms of profitability, TEVA's ROE is +0.06%, compared to DERM's ROE of -0.20%. Regarding short-term risk, TEVA is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check DERM's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, CRDL has a market cap of 121.9M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while CRDL trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas CRDL's P/E ratio is -4.02. In terms of profitability, TEVA's ROE is +0.06%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, TEVA is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CRDL's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, OGI has a market cap of 120.4M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while OGI trades at $0.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas OGI's P/E ratio is 1.92. In terms of profitability, TEVA's ROE is +0.06%, compared to OGI's ROE of +0.21%. Regarding short-term risk, TEVA is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check OGI's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TEVA's ROE is +0.06%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TEVA is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check SCTL's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, BGM has a market cap of 110.4M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while BGM trades at $8.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas BGM's P/E ratio is -1.81. In terms of profitability, TEVA's ROE is +0.06%, compared to BGM's ROE of -0.05%. Regarding short-term risk, TEVA is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check BGM's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas PROC's P/E ratio is 1.53. In terms of profitability, TEVA's ROE is +0.06%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TEVA is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check PROC's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TEVA's ROE is +0.06%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, TEVA is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check OPTN's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TEVA's ROE is +0.06%, compared to ZOM's ROE of -0.14%. Regarding short-term risk, TEVA is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZOM's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, CPIX has a market cap of 91.7M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while CPIX trades at $6.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas CPIX's P/E ratio is -15.30. In terms of profitability, TEVA's ROE is +0.06%, compared to CPIX's ROE of +2.03%. Regarding short-term risk, TEVA is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CPIX's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TEVA's ROE is +0.06%, compared to GRVI's ROE of +114.74%. Regarding short-term risk, TEVA is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check GRVI's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ZYBT has a market cap of 71.6M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ZYBT trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ZYBT's P/E ratio is -7.55. In terms of profitability, TEVA's ROE is +0.06%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, TEVA is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZYBT's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TEVA's ROE is +0.06%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TEVA is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZYNE's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TEVA's ROE is +0.06%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TEVA is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SSIC's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TEVA's ROE is +0.06%, compared to VLNS's ROE of N/A. Regarding short-term risk, TEVA is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check VLNS's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TEVA's ROE is +0.06%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, TEVA is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check DRRX's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, TLPH has a market cap of 54.5M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while TLPH trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas TLPH's P/E ratio is -3.89. In terms of profitability, TEVA's ROE is +0.06%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, TEVA is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TLPH's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, INCR has a market cap of 51.2M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while INCR trades at $3.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas INCR's P/E ratio is -4.16. In terms of profitability, TEVA's ROE is +0.06%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TEVA is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check INCR's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TEVA's ROE is +0.06%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, TEVA is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check JUPW's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas QLI's P/E ratio is -4.92. In terms of profitability, TEVA's ROE is +0.06%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TEVA is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check QLI's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TEVA's ROE is +0.06%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TEVA is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check HEXO's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while RMTI trades at $7.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas RMTI's P/E ratio is -5.28. In terms of profitability, TEVA's ROE is +0.06%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, TEVA is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check RMTI's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, SHPH has a market cap of 25M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while SHPH trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas SHPH's P/E ratio is -0.24. In terms of profitability, TEVA's ROE is +0.06%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, TEVA is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SHPH's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TEVA's ROE is +0.06%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TEVA is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check CYTH's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, CPHI has a market cap of 22.7M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while CPHI trades at $0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas CPHI's P/E ratio is -1.23. In terms of profitability, TEVA's ROE is +0.06%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, TEVA is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CPHI's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, TXMD has a market cap of 20.8M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while TXMD trades at $1.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas TXMD's P/E ratio is 91.70. In terms of profitability, TEVA's ROE is +0.06%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, TEVA is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TXMD's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, AYTU has a market cap of 20M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while AYTU trades at $1.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas AYTU's P/E ratio is -1.56. In terms of profitability, TEVA's ROE is +0.06%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, TEVA is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AYTU's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TEVA's ROE is +0.06%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, TEVA is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check EVOK's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TEVA's ROE is +0.06%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, TEVA is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ACRX's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, OPTH has a market cap of 13.7M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while OPTH trades at $2.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas OPTH's P/E ratio is -1.54. In terms of profitability, TEVA's ROE is +0.06%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, TEVA is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check OPTH's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TEVA's ROE is +0.06%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TEVA is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AGRX's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, CABR has a market cap of 8.6M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while CABR trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas CABR's P/E ratio is -1.21. In terms of profitability, TEVA's ROE is +0.06%, compared to CABR's ROE of -3.86%. Regarding short-term risk, TEVA is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CABR's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, INM has a market cap of 8.5M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while INM trades at $15.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas INM's P/E ratio is -5.07. In terms of profitability, TEVA's ROE is +0.06%, compared to INM's ROE of -3.04%. Regarding short-term risk, TEVA is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check INM's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TEVA's ROE is +0.06%, compared to NLTX's ROE of -0.44%. Regarding short-term risk, TEVA is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check NLTX's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas LCI's P/E ratio is -0.04. In terms of profitability, TEVA's ROE is +0.06%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TEVA is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check LCI's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TEVA's ROE is +0.06%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TEVA is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ADMP's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, SNOA has a market cap of 5.9M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while SNOA trades at $1.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas SNOA's P/E ratio is -1.12. In terms of profitability, TEVA's ROE is +0.06%, compared to SNOA's ROE of -0.36%. Regarding short-term risk, TEVA is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SNOA's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, SBFM has a market cap of 5.8M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while SBFM trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas SBFM's P/E ratio is -0.45. In terms of profitability, TEVA's ROE is +0.06%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, TEVA is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SBFM's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas MNK's P/E ratio is -0.44. In terms of profitability, TEVA's ROE is +0.06%, compared to MNK's ROE of -0.33%. Regarding short-term risk, TEVA is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check MNK's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, YCBD has a market cap of 4.4M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while YCBD trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas YCBD's P/E ratio is -0.97. In terms of profitability, TEVA's ROE is +0.06%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TEVA is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check YCBD's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TEVA's ROE is +0.06%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, TEVA is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check FLGC's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, SBFMW has a market cap of 4.2M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while SBFMW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas SBFMW's P/E ratio is N/A. In terms of profitability, TEVA's ROE is +0.06%, compared to SBFMW's ROE of -0.24%. Regarding short-term risk, TEVA is more volatile compared to SBFMW. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check SBFMW's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, GELS has a market cap of 3.9M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while GELS trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas GELS's P/E ratio is -0.96. In terms of profitability, TEVA's ROE is +0.06%, compared to GELS's ROE of -0.36%. Regarding short-term risk, TEVA is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check GELS's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TEVA's ROE is +0.06%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TEVA is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check PLXP's competition here

Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 50.4B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TEVA is priced at $43.24 on the NYSE, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of 14.75, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TEVA's ROE is +0.06%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TEVA is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ATNX's competition here